Neurodegenerative Disease Therapeutics Industry Data Book - Parkinson’s Disease Treatment and Alzheimer's Therapeutics Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030

Chapter 1 Methodology and Scope

•       1.1 Market Segmentation
•          1.1.1 Estimates And Forecast Timeline
•       1.2 Research Methodology
•       1.3 Information Procurement
•          1.3.1 Purchased Database
•          1.3.2 GVR’s Internal Database
•          1.3.3 Secondary Sources
•          1.3.4 Primary Research
•          1.3.5 Details Of Primary Research
•       1.4 Information Or Data Analysis
•          1.4.1 Data Analysis Models
•       1.5 Market Formulation & Validation
•       1.6 Model Details
•          1.6.1 Commodity Flow Analysis
•                1.6.1.1 Approach 1: Commodity Flow Approach
•                1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
•       1.7 Global Market: CAGR Calculation
•       1.8 Research Assumptions
•       1.9 List of Secondary Sources
•       1.10 List of Primary Sources
•       1.11 Objectives
•          1.11.1 Objective 1
•          1.11.2 Objective 2
•       1.12 List Of Abbreviations

Chapter 2 Market Definitions

•       2.1 Definitions

Chapter 3 Executive Summary

•       3.1 Market Summary

Chapter 4 Global Neurodegenerative Disease Treatment Variables, Trends, & Scope

•       4.1 Neurodegenerative Disease Treatment Market Lineage Outlook
•          4.1.1 Parent Market Outlook
•       4.2 Penetration And Growth Prospect Mapping
•       4.3 Regulatory Framework
•       4.4 Market Driver Analysis
•          4.4.1 Increasing Prevalence
•          4.4.2 Presence of Strong Pipeline Products
•          4.4.3 Increasing Funding for Neurodegenerative Disease Treatment
•          4.4.4 Growing Awareness
•          4.4.5 Introduction of Novel Drug Delivery Systems
•       4.5 Market Restraint Analysis
•          4.5.1 High Treatment Cost
•          4.5.2 Stringent Regulatory Policies
•       4.6 Value Chain Analysis
•          4.6.1 Value Chain Analysis/Route To Market
•       4.7 Consumer Behavior Analysis
•       4.8 Major Deals and Strategic Alliances Analysis
•          4.8.1 New product launch
•          4.8.2 Mergers and acquisitions
•          4.8.3 Expansion
•          4.8.4 Partnerships
•          4.8.5 Marketing & promotions
•          4.8.6 Market entry strategies
•       4.9 Parkinson’s Disease Treatment Market Analysis Tools
•          4.9.1 Industry Analysis - Porter’s
•          4.9.2 SWOT Analysis, By Pest
•       4.10 Alzheimer’s Therapeutics Market Analysis Tools
•          4.10.1 Industry Analysis - Porter’s
•          4.10.2 SWOT Analysis, By Pest

Chapter 5 Neurodegenerative Disease Treatment Market - Segment Analysis, by Drug Class, 2018 - 2030 (USD Million)

•       5.1 Neurodegenerative Disease Treatment Market: Drug Class Movement Analysis
•          5.1.1 Neurodegenerative Disease Treatment Market Estimates And Forecast, 2018 - 2030 (USD Million)
•       5.2 Parkinson’s Disease Treatment
•          5.2.1 Parkinson’s Disease Treatment Market Estimates And Forecast, 2018 - 2030 (USD Million)
•          5.2.2 Carbidopa-Levodopa
•                5.2.2.1 Carbidopa-Levodopa Market Estimates And Forecast, 2018 - 2030 (USD Million)
•          5.2.3 Dopamine Agonists
•                5.2.3.1 Dopamine Agonists Market Estimates And Forecast, 2018 - 2030 (USD Million)
•          5.2.4 MAO-B Inhibitors
•                5.2.4.1 MAO-B Inhibitors Market Estimates And Forecast, 2018 - 2030 (USD Million)
•          5.2.5 COMT Inhibitors
•                5.2.5.1 COMT Inhibitors Market Estimates And Forecast, 2018 - 2030 (USD Million)
•          5.2.6 Anticholinergics
•                5.2.6.1 Anticholinergics Market Estimates And Forecast, 2018 - 2030 (USD Million)
•          5.2.7 Others
•                5.2.7.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
•       5.3 Alzheimer’s Therapeutics
•          5.3.1 Alzheimer’s Therapeutics Market Estimates And Forecast, 2018 - 2030 (USD Million)
•          5.3.2 Serum Neurodegenerative Disease Treatment
•                5.3.2.1 Serum Neurodegenerative Disease Treatment Market Estimates And Forecast, 2018 - 2030 (USD Million)
•          5.3.3 Cholinesterase Inhibitors
•                5.3.3.1 Cholinesterase Inhibitors Market Estimates And Forecast, 2018 - 2030 (USD Million)
•          5.3.4 NMDA Receptor Antagonist
•                5.3.4.1 NMDA Receptor Antagonist Market Estimates And Forecast, 2018 - 2030 (USD Million)
•          5.3.5 Combination Drug
•                5.3.5.1 Combination Drug Market Estimates And Forecast, 2018 - 2030 (USD Million)
•          5.3.6 Pipeline Drugs
•                5.3.6.1 Pipeline Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Neurodegenerative Disease Treatment Market - Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

•       6.1 Neurodegenerative Disease Treatment Market: End-use Movement Analysis
•       6.2 Hospital Pharmacy
•          6.2.1 Hospital Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
•       6.3 Retail Pharmacy
•          6.3.1 Retail Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
•       6.4 Online Pharmacy
•          6.4.1 Online Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 Neurodegenerative Disease Treatment Market - Segment Analysis, by Region, 2018 - 2030 (USD Million)

•       7.1 Neurodegenerative Disease Treatment Market: Regional Movement Analysis
•       7.2 North America
•          7.2.1 North America, SWOT Analysis
•          7.2.2 North America Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.2.3 U.S.
•                7.2.3.1 U.S. Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.2.4 Canada
•                7.2.4.1 Canada Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•       7.3 Europe
•          7.3.1 Europe, SWOT Analysis
•          7.3.2 Europe Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.3.3 U.K.
•                7.3.3.1 U.K. Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.3.4 Germany
•                7.3.4.1 Germany Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.3.5 Spain
•                7.3.5.1 Spain Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.3.6 France
•                7.3.6.1 France Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.3.7 Italy
•                7.3.7.1 Italy Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.3.8 Russia
•                7.3.8.1 Russia Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.3.9 Russia
•                7.3.9.1 Russia Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.3.10 Norway
•                7.3.10.1 Norway Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.3.11 Sweden
•                7.3.11.1 Sweden Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.3.12 Denmark
•                7.3.12.1 Denmark Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•       7.4 Asia Pacific
•          7.4.1 Asia Pacific, SWOT Analysis
•          7.4.2 Asia Pacific Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.4.3 Japan
•                7.4.3.1 Japan Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.4.4 China
•                7.4.4.1 China Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.4.5 India
•                7.4.5.1 India Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.4.6 South Korea
•                7.4.6.1 South Korea Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.4.7 Singapore
•                7.4.7.1 Singapore Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.4.8 Australia
•                7.4.8.1 Australia Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.4.9 Thailand
•                7.4.9.1 Thailand Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•       7.5 Latin America
•          7.5.1 Latin America, SWOT Analysis
•          7.5.2 Latin America Market Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.5.3 Brazil
•                7.5.3.1 Brazil Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.5.4 Mexico
•                7.5.4.1 Mexico Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.5.5 Argentina
•                7.5.5.1 Argentina Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•       7.6 Middle East and Africa
•          7.6.1 Middle East & Africa, SWOT Analysis
•          7.6.2 Middle-East And Africa Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.6.3 South Africa
•                7.6.3.1 South Africa Market Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.6.4 United Arab Emirates
•                7.6.4.1 United Arab Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.6.5 Saudi Arabia
•                7.6.5.1 Saudi Arabia Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
•          7.6.6 Kuwait
•                7.6.6.1 Kuwait Neurodegenerative Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Competitive Analysis

•       8.1 Recent Developments & Impact Analysis, By Key Market Participants
•          8.1.1 Ansoff Matrix
•          8.1.2 Company/Competition Categorization (Key Innovators, Market Leaders, Expansion)
•          8.1.3 Innovators
•       8.2 Vendor Landscape
•          8.2.1 List Of Key Distributors And Channel Partners
•          8.2.2 Global Parkinson’s Disease Treatment Market: Key Company Market Share Analysis, 2021
•          8.2.3 Global Alzheimer’s Therapeutics Market: Key Company Market Share Analysis, 2021
•          8.2.4 Global Neurodegenerative Disease Treatment Market: Key Company Market Share Analysis, 2021
•       8.3 Public Companies
•          8.3.1 Company Market Position Analysis
•          8.3.2 Competitive Dashboard Analysis
•          8.3.3 Strategic Framework
•       8.4 Private Companies
•          8.4.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
•          8.4.2 Regional Network Map
•       8.5 Company Profiles
•          8.5.1 Cerevel Therapeutics
•                8.5.1.1 Company Overview
•                8.5.1.2 Alere, Inc.
•                8.5.1.3 Financial Performance
•                8.5.1.4 Product Benchmarking
•                8.5.1.5 Strategic Initiatives
•          8.5.2 Novartis AG
•                8.5.2.1 Company Overview
•                8.5.2.2 Financial Performance
•                8.5.2.3 Product Benchmarking
•                8.5.2.4 Strategic Initiatives
•          8.5.3 Teva Pharmaceutical Industries Ltd.
•                8.5.3.1 Company Overview
•                8.5.3.2 Financial Performance
•                8.5.3.3 Product Benchmarking
•                8.5.3.4 Strategic Initiatives
•          8.5.4 Merck & Co., Inc.
•                8.5.4.1 Company Overview
•                8.5.4.2 Financial Performance
•                8.5.4.3 Product Benchmarking
•                8.5.4.4 Strategic Initiatives
•          8.5.5 GlaxoSmithKline plc. (GSK)
•                8.5.5.1 Company Overview
•                8.5.5.2 Financial Performance
•                8.5.5.3 Product Benchmarking
•                8.5.5.4 Strategic Initiatives
•          8.5.6 AbbVie, Inc.
•                8.5.6.1 Company Overview
•                8.5.6.2 Financial Performance
•                8.5.6.3 Product Benchmarking
•                8.5.6.4 Strategic Initiatives
•          8.5.7 H. Lundbeck A/S
•                8.5.7.1 Company Overview
•                8.5.7.2 Financial Performance
•                8.5.7.3 Product Benchmarking
•                8.5.7.4 Strategic Initiatives
•          8.5.8 Amneal Pharmaceuticals LLC.
•                8.5.8.1 Company Overview
•                8.5.8.2 Financial Performance
•                8.5.8.3 Product Benchmarking
•                8.5.8.4 Strategic Initiatives
•          8.5.9 Supernus Pharmaceuticals, Inc.
•                8.5.9.1 Company Overview
•                8.5.9.2 Financial Performance
•                8.5.9.3 Product Benchmarking
•                8.5.9.4 Strategic Initiatives
•          8.5.10 Eisai Co., Ltd.
•                8.5.10.1 Company Overview
•                8.5.10.2 Financial Performance
•                8.5.10.3 Product Benchmarking
•                8.5.10.4 Strategic Initiatives
•          8.5.11 Adamas Pharmaceuticals, Inc.
•                8.5.11.1 Company Overview
•                8.5.11.2 Financial Performance
•                8.5.11.3 Product Benchmarking
•                8.5.11.4 Strategic Initiatives
•          8.5.12 Biogen
•                8.5.12.1 Company Overview
•                8.5.12.2 Financial Performance
•                8.5.12.3 Product Benchmarking
•                8.5.12.4 Strategic Initiatives
•          8.5.13 AC Immune
•                8.5.13.1 Company Overview
•                8.5.13.2 Financial Performance
•                8.5.13.3 Product Benchmarking
•                8.5.13.4 Strategic Initiatives
•          8.5.14 DAIICHI SANKYO COMPANY, LIMITED
•                8.5.14.1 Company Overview
•                8.5.14.2 Financial Performance
•                8.5.14.3 Product Benchmarking
•                8.5.14.4 Strategic Initiatives
•          8.5.15 Johnson & Johnson Services Inc.
•                8.5.15.1 Company Overview
•                8.5.15.2 Financial Performance
•                8.5.15.3 Product Benchmarking
•                8.5.15.4 Strategic Initiatives
•          8.5.16 TauRx Pharmaceuticals Ltd.
•                8.5.16.1 Company Overview
•                8.5.16.2 Financial Performance
•                8.5.16.3 Product Benchmarking
•                8.5.16.4 Strategic Initiatives
•          8.5.17 F. Hoffmann La Roche Ltd.
•                8.5.17.1 Company Overview
•                8.5.17.2 Financial Performance
•                8.5.17.3 Product Benchmarking
•                8.5.17.4 Strategic Initiatives